For the quarter ending 2026-03-31, DMIIR has $509,725,411 in assets. $18,166,285 in debts.
| Balance Sheets | 2026-03-31 | 2025-12-31 | ||
|---|---|---|---|---|
| Cash | 347,720 | 223 | ||
| Prepaid expenses | 4,041 | 25,814 | ||
| Total current assets | 351,761 | 26,037 | ||
| Cash and investments held in trust account | 509,373,650 | 504,933,800 | ||
| Total non-current assets | 509,373,650 | 504,933,800 | ||
| Total assets | 509,725,411 | 504,959,837 | ||
| Accounts payable | 49,166 | 99,359 | ||
| Accrued expenses | 53,957 | 88,343 | ||
| Accrued offering costs | 113,162 | 113,162 | ||
| Promissory notes | 450,000 | - | ||
| Total current liabilities | 666,285 | 300,864 | ||
| Deferred underwriting fee payable | 17,500,000 | 17,500,000 | ||
| Total non-current liabilities | 17,500,000 | 17,500,000 | ||
| Total liabilities | 18,166,285 | 17,800,864 | ||
| Ordinary shares subject to possible redemption, 50,000,000 shares at redemption value of 10.19 and 10.10 per share as of march 31, 2026 and december 31, 2025, respectively | 509,373,650 | 504,933,800 | ||
| Ordinary shares, 0.0001 par value 220,000,000 shares authorized 13,700,000 shares issued and outstanding, excluding 50,000,000 shares subject to redemption as of march 31, 2026 and december 31, 2025 | 1,369 | 1,369 | ||
| Accumulated deficit | -17,815,893 | -17,776,196 | ||
| Total shareholders deficit | -17,814,524 | -17,774,827 | ||
| Total liabilities, ordinary shares subject to possible redemption, and shareholders deficit | 509,725,411 | 504,959,837 | ||
Drugs Made In America Acquisition II Corp. (DMIIR)
Drugs Made In America Acquisition II Corp. (DMIIR)